Join Dr. Paul Feuerstadt, along with Dr. Darrell Pardi and Dr. Sahil Khanna from the Mayo Clinic, for a timely and in-depth discussion on Clostridioides difficile (C. difficile) infection, recorded live at GI ReConnect in Denver. In this expert roundtable, the panel explores shifting epidemiology trends, the evolution of diagnostic testing algorithms, and best practices for managing both initial and recurrent C. diff cases. They weigh the clinical impact of the discontinuation of bezlotoxumab, discuss updated treatment strategies—including fidaxomicin use and the role of extended-pulsed regimens—and examine the emerging use of FDA-approved microbiome restoration therapies such as REBYOTA® and VOWST®. With practical insights on interpreting discordant toxin assays, managing high-risk or immunocompromised patients, and addressing fulminant cases in critical care, this conversation offers gastroenterologists, infectious disease specialists, and primary care providers essential guidance on navigating an increasingly complex therapeutic landscape. The group also addresses the implications of OpenBiome's closure, the promise of cost-effective options as fidaxomicin nears patent expiration, and the importance of individualized, risk-based care in preventing recurrence and improving outcomes.

Ver todos los episodios